Inflammatory Mechanisms and Treatments of Alzheimer's Disease: An Integrative Review of Neuroscience and Bioinformatics

Bangyu Li

doi:10.62051/vhm52808

Authors

Bangyu Li

DOI:

https://doi.org/10.62051/vhm52808

Keywords:

Alzheimer’s disease; Neuroinflammation; Microglia; Astrocytes; Cytokines.

Abstract

The most common type of dementia, Alzheimer's disease (AD), is characterized by plaques of amyloid-beta (Aβ) and then tangles of tau protein aggregating in the brain, causing neurodegeneration and cognitive decline. The association between neuroinflammation and the pathogenesis of AD has come to be increasingly well acknowledged. This review discusses the inflammatory pathways involved in AD, focusing on microglia and astrocytes, as well as the involvement of various proinflammatory cytokines (i.e., TNF-α and IL-1β). The NF-κB signaling and the NLRP3 inflammasome are also reviewed for their effects on neuronal death and cognitive dysfunction. Additionally, the unifying function of bioinformatics in AD research, combining genomic and transcriptomic analyses with proteomics and metabolomics, is explored. These tools have uncovered crucial genetic and molecular pathways associated with inflammatory cross-talks in AD, revealing possible drug targets. An overview of treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), immunotherapies, and newer therapies like stem cell therapy and RNA interference is provided, along with their efficacy and drawbacks. The review concludes by highlighting the importance of multidisciplinary approaches and individualized therapies to enhance therapeutic outcomes in AD patients.

Downloads

Download data is not yet available.

References

[1] Wiatrak, B., et al. (2023). Does inflammation play a major role in the pathogenesis of Alzheimer's disease? Neuromolecular Medicine, 25 (3), 330 - 335.

[2] Qin, J., et al. (2023). Microglia activation in central nervous system disorders: A review of recent mechanistic investigations and development efforts. Frontiers in Neurology, 14, 1103416.

[3] Araque, A., & Navarrete, M. (2010). Glial cells in neuronal network function. Philosophical Transactions of the Royal Society B: Biological Sciences, 365 (1551), 2375 - 2381.

[4] Buxbaum, J. D., et al. (1992). Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proceedings of the National Academy of Sciences of the United States of America, 89 (21), 10075 - 10078.

[5] Chang, R., Yee, K. L., & Sumbria, R. K. (2017). Tumor necrosis factor α inhibition for Alzheimer's disease. Journal of Central Nervous System Disease, 9, 1179573517709278.

[6] Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017). Targeting tumor necrosis factor alpha for Alzheimer's disease. Current Alzheimer Research, 14 (4), 412 - 425.

[7] Sartori, A. C., et al. (2012). The impact of inflammation on cognitive function in older adults: Implications for healthcare practice and research. Journal of Neuroscience Nursing, 44 (4), 206 - 217.

[8] Zhang, Z. G., et al. (2015). Inflammation in Alzheimer's disease and molecular genetics: Recent update. Archives of Immunology and Therapy Experiment (Warszawa), 63 (5), 333 - 344.

[9] Hwang, B., Lee, J. H., & Bang, D. (2018). Single-cell RNA sequencing technologies and bioinformatics pipelines. Experimental & Molecular Medicine, 50 (8), 1 - 14.

[10] Potter, S. S. (2018). Single-cell RNA sequencing for the study of development, physiology and disease. Nature Reviews Nephrology, 14 (8), 479 - 492.

[11] Zhang, Y., et al. (2021). Single-cell RNA sequencing in cancer research. Journal of Experimental & Clinical Cancer Research, 40 (1), 81. Zhao, J., Y. Shi, and G. Cao, The Application of Single-Cell RNA Sequencing in the Inflammatory Tumor Microenvironment. Biomolecules, 2023. 13 (2).

[12] Clough, E., & Barrett, T. (2016). The Gene Expression Omnibus Database. Methods in Molecular Biology, 1418, 93 - 110.

[13] Shah, T. R., & Misra, A. (2011). Proteomics. In A. Misra (Ed.), Challenges in Delivery of Therapeutic Genomics and Proteomics (pp. 387-427). London: Elsevier.

[14] Okoye, C. O., et al. (2023). The performance of lactic acid bacteria in silage production: A review of modern biotechnology for silage improvement. Microbiological Research, 266, 127212.

[15] Johnson, E. C. B., et al. (2020). Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 26 (5), 769 - 780.

[16] El Idrissi, F., et al. (2021). A computational exploration of the molecular network associated with neuroinflammation in Alzheimer's disease. Frontiers in Pharmacology, 12, 630003.

[17] Gurdon, B., & Kaczorowski, C. (2021). Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models. Neurobiology of Disease, 161, 105558.

[18] Li, Q., et al. (2023). Virtual screening-based drug development for the treatment of nervous system diseases. Current Neuropharmacology, 21 (12), 2447 - 2464.

[19] Gan, J.-h., et al. (2023). DrugRep: An automatic virtual screening server for drug repurposing. Acta Pharmacologica Sinica, 44 (4), 888 - 896.

[20] Phillips, W. J., & Currier, B. L. (2004). Analgesic pharmacology: II. Specific analgesics. Journal of the American Academy of Orthopaedic Surgeons, 12 (4), 221 - 233.

[21] Zhang, C., et al. (2018). NSAID exposure and risk of Alzheimer's disease: An updated meta-analysis from cohort studies. Frontiers in Aging Neuroscience, 10, 83.

[22] Huang, L. K., et al. (2023). Clinical trials of new drugs for Alzheimer disease: A 2020-2023 update. Journal of Biomedical Science, 30 (1), 83.

[23] Verger, A., et al. (2023). FDA approval of lecanemab: The real start of widespread amyloid PET use? - The EANM Neuroimaging Committee perspective. European Journal of Nuclear Medicine and Molecular Imaging, 50 (6), 1553 - 1555.

[24] Yi, L. X., Tan, E. K., & Zhou, Z. D. (2024). Passive immunotherapy for Alzheimer's disease: Challenges & future directions. Journal of Translational Medicine, 22 (1), 430.

[25] Bascones-Martinez, A., et al. (2014). Immunomodulatory drugs: Oral and systemic adverse effects. Medicina Oral, Patología Oral y Cirugía Bucal, 19 (1), e24 - e31.

[26] Arnon, R., & Aharoni, R. (2019). Glatiramer acetate: From bench to bed and back. Israel Medical Association Journal, 21 (3), 151 - 157.

[27] Bali, P., et al. (2017). Potential for stem cells therapy in Alzheimer's disease: Do neurotrophic factors play critical role? Current Alzheimer Research, 14 (2), 208 - 220.

[28] Lucke-Wold, B. P., et al. (2016). Aneurysmal subarachnoid hemorrhage and neuroinflammation: A comprehensive review. International Journal of Molecular Sciences, 17 (4), 497.

[29] Duan, Y., Lyu, L., & Zhan, S. (2023). Stem cell therapy for Alzheimer's disease: A scoping review for 2017-2022. Biomedicines, 11 (1).